Day OneTuesday, March 9, 2027 - Eastern Daylight Time (EDT)

A fast-paced, global view on how capital is flowing across seed, venture, crossover, and public markets as investors recalibrate risk. Hear how managers are retooling portfolios, where dry powder is being deployed, and what milestones matter now for unlocking each financing stage.

• How valuation resets are reshaping round sizes, syndicates, and insider participation from seed to Series C+ and beyond
• Which signals open the crossover window in 2027 (clinical proof points, platform validation, commercial proximity)
• Practical tactics for extending runway and sequencing catalysts to attract new capital
  
  

From precision oncology to immunology, radiopharmaceuticals, and neuroscience, capital concentration is shifting as investors chase clear clinical readouts and commercial line of sight. Get a data-backed take on where funding is clustering—and where contrarians see alpha.

• Subsector theses with favorable risk-adjusted profiles and near-term value inflection
• Platform versus asset plays: when breadth helps and when focus wins
• How can early-stage companies demonstrably de-risk novel mechanisms to attract investors and strategic partners?

The medtech sector has undergone seismic transformation since 2020—from supply chain upheavals and regulatory pivots to accelerated digital adoption and shifting reimbursement models. As we move deeper into 2027, the dust has settled, but has the landscape fundamentally changed?

• Permanent shifts vs. temporary disruptions: separating lasting change from pandemic noise
• Recalibrated priorities: how R&D pipelines, commercial models, and stakeholder expectations have evolved
• Winning in the new paradigm: strategies for thriving amid regulatory evolution, care delivery transformation, and market consolidation
  
  

Join industry pioneers as they decode the critical success factors transforming biotech startups into market leaders. This dynamic panel explores the intersection of scientific innovation, strategic capital deployment, and governance frameworks that drive sustainable growth in today's rapidly evolving life sciences landscape

• Capital & Scale: How do biotech leaders balance aggressive growth ambitions with capital efficiency while navigating the challenging path from Series A to IPO and beyond?
• Governance as Competitive Advantage: What governance structures and board compositions enable biotech companies to make faster, smarter decisions while maintaining regulatory compliance and stakeholder confidence?
• Value Creation Beyond Valuation: How are leading biotech executives redefining success metrics to encompass patient outcomes, partnership ecosystems, and long-term strategic positioning rather than focusing solely on exit multiples?

Angel investors write the first checks that transform scientific ideas into are often the first investors beyond friends/family to support early stage companies —but what exactly are they looking for, and how do they think about risk and valuation at the earliest stages? This panel assembles active life sciences angels to demystify their investment approach, share what separates compelling opportunities from passes, and explain how angel rounds set the foundation for institutional capital.

• How angels evaluate opportunities, approach valuation, and decide to invest when there's more vision than data
• The angel ecosystem today: deal flow, syndication, and the evolving role of individual investors
• Bridging to institutional capital: what differentiates an angel round from Series A, and how to position for the next stage

In preclinical biotech, scientific promise needs strategic de-risking to command premium valuations. This panel reveals how investors and dealmakers assess mechanism risk, translate data quality into confidence, and engineer value inflections through smart partnerships and milestones. Learn to bridge early science and market credibility, structure deals that compound value pre-IND, and build a defensible edge that resonates with partners and backers in a competitive landscape.

• Valuing science under uncertainty: mechanism and modality risk, translational confidence, and data quality that actually move price
• Engineering value inflections: smart partnerships, platform extensions, and milestone maps that compound value before IND
• Proving the upside: real addressable market, access dynamics, and a defendable edge against incumbents and emerging rivals

Women's health innovation is persistently underfunded and underinvested. This gap of huge social value is also a massive opportunity for pharma. As pharma companies increasingly recognise the commercial potential and actively seek assets across reproductive health, menopause, maternal health, and female-specific conditions, this panel examines where capital is flowing, what makes a women's health asset attractive to strategic buyers, and how companies can position themselves to capture this accelerating market demand.

• Why Now?:What's driving the recent surge in pharma interest and investment in women's health, and which therapeutic areas are commanding the highest valuations and deal activity?
• What Pharma is Looking For: Beyond unmet need, what clinical, commercial, and regulatory characteristics make a women's health asset acquisition-ready, and how should companies design their development strategies accordingly?
• Building for Exit or Scale: How do emerging women's health companies balance building standalone commercial capabilities with positioning for strategic partnership or acquisition

With patent cliffs looming, big pharma is sharpening its external innovation strategy. Hear straight from BD leaders on what excites them in 2027, how they assess platform durability versus single-asset risk, and what compels them to champion a deal internally.

• Therapeutic areas and modalities at the top of BD priority matrices this year
• Internal advocacy: what data, endpoints, and differentiation secure governance approval
• Deal terms and diligence signals that correlate with faster decision cycles